Press Release

Newsweek International Features ASKA PharmaceuticalTOKYO, March 21, 2024 - ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886) is pleased toannounce that Sohta Yamaguchi, President, Representative Director of its subsidiary, ASKA
Pharmaceutical Co., Ltd. (hereinafter “ASKA”), was interviewed by the news agency, theWorldfolio PTE. LTD. and the article introducing ASKA was published in the US weekly magazine“Newsweek International.” Please see the attached for the article content.
Reference: Newsweek International Features ASKA Pharmaceutical (aska-pharma-hd.co.jp)* announced on September 14, 2023
Newsweek is an American weekly magazine with a global readership of approximately 46 million
people, and provides information on all areas of global culture, politics, economics, and socialconditions. For the special feature “The Japanese Firms Accelerating Medical Innovation,”
Newsweek introduced ASKA as one of the firms in this issue.
The full interview is posted on the news website “The WORLDFOLIO.”
https://www.theworldfolio.com/interviews/aska-we-create-new-value-as-leading-womenshealthcare-company/5872/* The Worldfolio PTE. LTD. has granted permission to post the article here.
The Worldfolio PTE. LTD.：
The Worldfolio is a media agency and a news website that has been bringing high-quality content
to readers around the globe for over 20 years. The Worldfolio PTE LTD is now based in Singapore
and provides breaking news, in-depth analyses, and investigative stories about a wide range oftopics and sectors, including manufacturing, real estate, construction, healthcare, digitaltransformation and more.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp

The World's Best Hospitals

HOSPITALBOSSES ARE
BETTING ON

BIG TECH

1 5 . 0 3 . 2 0 2 4
ALBANIA €6.25
DENMARK DKR57
AUSTRALIA $11.00 EGYPT E£ 65.00
AUSTRIA €10.00
FINLAND €7.60
BAHRAIN BD4.25
FRANCE €7.50
BELGIUM €7.00
GERMANY €7.50
CHINA RM80
GIBRALTAR £6.05
CYPRUS €7.00
GREECE €7.50
CZECH REP CZK180 HOLLAND €7.00

HONG KONG HK80
LITHUANIA €8.99
HUNGARY HUF 5.990 LUXEMBOURG €7.90
IRELAND €7.00
MALTA €7.00
ISRAEL NIS35
MONTENEGRO €8.30
ITALY €7.00
MOROCCO MDH70
KUWAIT KD3.00
NEW ZEALAND $14.00
LATVIA €6.50
NIGERIA $3.40C
LEBANON LL10,000 NORWAY NKR119OMAN OR 3.250
POLAND PLN29.99
PORTUGAL €7.00
QATAR QR65
MALAYSIA RM27.90
ROMANIA LEI 42.00
SAUDI ARABIA SR35.00
S LEONE SLL30,000

SINGAPORE $11.95
SLOVAKIA €6.50
SOUTH AFRICA R55.00
SPAIN €7.00
SWEDEN SKR119SWITZERLAND
CHF10.60
UAE AED42UK £5.99
US $10.99
ZIMBABWE ZWD4.00

ASKA Pharmaceutical: Revolutionizing Women’s Healthcare
In its drive to become awomen’s healthcare pioneer,
ASKA Pharmaceutical iscommitted to innovation andglobal expansion.

“We aim to becomea total healthcarecompany and a globalentity.”
Sohta Yamaguchi,President,
ASKA Pharmaceutical

Head ofﬁce in Tokyo
ASKA Pharmaceutical is today
the leading force in Japan’s obstetrics and gynecology sector,
showcasing a relentless pursuit ofexcellence in women’s healthcarethat demonstrates its commitment beyond mere sales ﬁgures.
“We aim to become a total healthcare company and a global entity,aligning with our corporate philosophy,” says Sohta Yamaguchi,
the company’s president.
ASKA’s strategic shift to a holdings model enables the company
to offer comprehensive healthservices, from prevention to post- drugs and treatments but alsotreatment, meeting the evolving medical equipment and related
needs of a proactive populace. services, offering comprehensive
With innovative products like RE- health services for females.”And in a world where selfLUMINA (relugolix) for uterine ﬁbroids and endometriosis, and es- medication is on the rise, ASKA
sential products in the treatment Pharmaceutical sees opportuniof thyroid disease, ASKA
ties, not obstacles. “OverPharmaceutical stands
the-counter options areout by providing effecgaining popularity,
tive solutions.
and this has led to“We offer drugs
the growing healththat provide treatconsciousness ofment options for
the Japanese people
women’s health chaland the revitalization
lenges at every stage ofof the healthcare marlife,” Mr. Yamaguchiket,” he adds.
Looking forward,explains. “We aim Three core areas with ato not only provide focus on pharmaceuticals Mr. Yamaguchi en-Drugs for the treatment of thyroid
disease when launched in 1922
visions a future where ASKA
expands globally, enriching lives
beyond Japan’s borders. “By our105th anniversary in 2025, I
hope to report our successfulachievements,” he shares, hinting
at forthcoming advancements inglobal expansion and new business ventures.
In a nutshell, ASKA Pharmaceutical isn’t just about treatingailments; it’s about empowering
women, fostering health awareness, and pioneering innovations
that transcend borders. With Mr.
Yamaguchi at the helm, the company’s journey towards global leadership in women’s health seems notjust promising but inevitable.
www.aska-pharma.co.jp